Pipeline — registered trials by phase
No registered trials in this stage.
A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
— · Obese Adults · Recruiting · est. 2027-05
A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities
— · Obese Adults · Recruiting · est. 2026-10-02
Phase 1 Study to Evaluate the Safety and Tolerability of VK2735
— · Weight Loss, NASH · Completed · est. 2024-11-04
A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN
— · Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) · Completed · est. 2024-10-09
VK2735 for Weight Management Phase 2
— · Weight Loss · Completed · est. 2024-02-27
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
— · Weight Loss · Completed · est. 2025-06-24
Acute Hip Fracture Study in Patients 65 Years or Greater
— · Hip Fractures · Completed · est. 2017-11-15
Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
— · Hyperlipidemia, NAFLD · Completed · est. 2019-03-26
A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH
— · NASH - Nonalcoholic Steatohepatitis · Completed · est. 2023-05-15
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
— · Weight Loss · Not Yet Recruiting · est. 2028-10
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
— · Weight Loss · Not Yet Recruiting · est. 2028-07
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
— · Weight Loss · Active Not Recruiting · est. 2027-07-01
VK2735 for Weight Management Phase 3
— · Weight Loss · Active Not Recruiting · est. 2027-07-01
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Viking Therapeutics is lead sponsor; 13 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-09-28Current report (material event)
- 424B52026-09-25Prospectus (offering)
- 424B52026-09-25Prospectus (offering)
- FWP2026-09-24FWP
- 305B22026-09-24305B2
- 424B52026-09-23Prospectus (offering)
- 424B52026-09-23Prospectus (offering)
- 8-K2026-09-22Current report (material event)
- S-3ASR2026-07-30S-3ASR
- 10-Q2026-07-29Quarterly report
- 8-K2026-07-29Current report (material event)
- 8-K2026-05-26Current report (material event)
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- 10-Q2026-04-30Quarterly report
- 8-K2026-04-29Current report (material event)
- ARS2026-04-01Annual report to holders
- DEFA14A2026-04-01DEFA14A
- DEF 14A2026-04-01Proxy statement
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 10-K2026-02-11Annual report
- 8-K2026-02-11Current report (material event)
- SCHEDULE 13G/A2025-11-05SCHEDULE 13G/A
- 10-Q2025-10-23Quarterly report
- 8-K2025-10-22Current report (material event)
- 8-K2025-08-19Current report (material event)
- SCHEDULE 13G/A2025-08-06SCHEDULE 13G/A
- 10-Q2025-07-23Quarterly report
- 8-K2025-07-23Current report (material event)
- 8-K2025-05-27Current report (material event)
- SCHEDULE 13G/A2025-05-12SCHEDULE 13G/A
- 10-Q2025-04-24Quarterly report
- DEFA14A2025-04-23DEFA14A
- DEFR14A2025-04-23DEFR14A
- 8-K2025-04-23Current report (material event)
- 8-K2025-04-23Current report (material event)
- SCHEDULE 13G/A2025-04-23SCHEDULE 13G/A
- UPLOAD2025-04-21UPLOAD
- CORRESP2025-04-08CORRESP
- ARS2025-04-08Annual report to holders
- DEFA14A2025-04-08DEFA14A
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.